Regnum Corp. (RGMP)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2022 | 2.02 Million USD | 8.38% |
| 2021 | 1.86 Million USD | 3304.34% |
| 2020 | 54.89 Thousand USD | 6761.63% |
| 2019 | 800.00 USD | -77.99% |
| 2018 | 3635.00 USD | 66.13% |
| 2017 | 2188.00 USD | 165.21% |
| 2016 | 825.00 USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q3 | - USD | 0.0% |
| 2023 Q1 | 1.84 Million USD | -8.8% |
| 2023 Q2 | - USD | -100.0% |
| 2022 Q4 | 2.02 Million USD | -2.04% |
| 2022 FY | 2.02 Million USD | 8.38% |
| 2022 Q2 | 2.2 Million USD | 7.36% |
| 2022 Q1 | 2.05 Million USD | 10.13% |
| 2022 Q3 | 2.06 Million USD | -6.42% |
| 2021 Q1 | 58.23 Thousand USD | 6.08% |
| 2021 Q4 | 1.86 Million USD | 1470.83% |
| 2021 Q3 | 118.96 Thousand USD | 471.45% |
| 2021 Q2 | 20.81 Thousand USD | -64.25% |
| 2021 FY | 1.86 Million USD | 3304.34% |
| 2020 Q4 | 54.89 Thousand USD | 3.62% |
| 2020 FY | 54.89 Thousand USD | 6761.63% |
| 2020 Q3 | 52.97 Thousand USD | 9.38% |
| 2020 Q1 | - USD | -100.0% |
| 2020 Q2 | 48.43 Thousand USD | 0.0% |
| 2019 FY | 800.00 USD | -77.99% |
| 2019 Q1 | 3635.00 USD | 0.0% |
| 2019 Q4 | 800.00 USD | -39.62% |
| 2019 Q3 | 1325.00 USD | 0.0% |
| 2019 Q2 | 1325.00 USD | -63.55% |
| 2018 Q1 | 2722.00 USD | 24.41% |
| 2018 FY | 3635.00 USD | 66.13% |
| 2018 Q4 | 3635.00 USD | 6.16% |
| 2018 Q3 | 3424.00 USD | 3.07% |
| 2018 Q2 | 3322.00 USD | 22.04% |
| 2017 Q1 | - USD | -100.0% |
| 2017 Q3 | 1325.00 USD | 0.0% |
| 2017 Q4 | 2188.00 USD | 65.13% |
| 2017 FY | 2188.00 USD | 165.21% |
| 2016 Q4 | 825.00 USD | 0.0% |
| 2016 FY | 825.00 USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -7283.031% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 78.603% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 97.205% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -150.421% |
| Rebus Holdings, Inc. | 5.24 Million USD | 61.362% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 96.568% |
| Qrons Inc. | 1.48 Million USD | -36.05% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -65.174% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 97.297% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -4431.473% |
| Skye Bioscience, Inc. | 14.07 Million USD | 85.607% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 96.2% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 78.863% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -380.441% |
| SQZ Biotechnologies Company | 50.03 Million USD | 95.952% |
| Intellipharmaceutics International Inc. | 12 Million USD | 83.134% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 47.412% |
| Mesoblast Limited | 188.44 Million USD | 98.925% |
| Marizyme, Inc. | 26.67 Million USD | 92.407% |
| Genus plc | 485 Million USD | 99.582% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 65.334% |
| Pharming Group N.V. | 244.07 Million USD | 99.17% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -0.759% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | 19.51% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 46.7% |
| ContraFect Corporation | 32.53 Million USD | 93.774% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -2.225% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 47.085% |
| IMV Inc. | 37.93 Million USD | 94.661% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 82.804% |
| MultiCell Technologies, Inc. | 1617.67 USD | -125103.966% |
| ONE Bio Corp. | 27.49 Million USD | 92.634% |
| Accustem Sciences Inc. | 1.07 Million USD | -87.668% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 97.384% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | 4.24% |
| Q BioMed Inc. | 8.13 Million USD | 75.096% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 97.558% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 60.642% |
| Biomind Labs Inc. | 1.49 Million USD | -35.151% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 98.294% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 77.601% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 88.995% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -41.254% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -1325.375% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -907.074% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 64.75% |
| GB Sciences, Inc. | 5.41 Million USD | 62.614% |
| Alpha Cognition Inc. | 7.16 Million USD | 71.731% |
| HST Global, Inc. | 593.59 Thousand USD | -241.208% |
| CSL Limited | 18.62 Billion USD | 99.989% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -60.848% |
| Halberd Corporation | 728.71 Thousand USD | -177.938% |
| Enzolytics Inc. | 365.26 Million USD | 99.446% |
| Agentix Corp. | 2.51 Million USD | 19.325% |
| Resverlogix Corp. | 67.39 Million USD | 96.995% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -141.482% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 99.545% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -18.167% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 91.815% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 82.984% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 44.74% |
| AVAX Technologies, Inc. | 3.99 Million USD | 49.286% |
| Zenith Capital Corp. | 27.56 Thousand USD | -7246.61% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.847% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -748.671% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 45.763% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -197.486% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | 25.308% |
| Kadimastem Ltd | 3.5 Million USD | 42.212% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -2926.173% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 95.971% |
| BioStem Technologies, Inc. | 15.9 Million USD | 87.265% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -335.849% |
| LadRx Corporation | 2.2 Million USD | 7.959% |
| Cell Source, Inc. | 15.8 Million USD | 87.187% |
| Regen BioPharma, Inc. | 5.45 Million USD | 62.889% |
| Regen BioPharma, Inc. | 5.45 Million USD | 62.889% |
| NovAccess Global Inc. | 7.86 Million USD | 74.234% |
| Affymax, Inc. | 8.87 Million USD | 77.168% |
| Itoco Inc. | 1.65 Million USD | -22.517% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | 1.276% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 66.517% |
| Mobile Lads Corp. | 1.31 Million USD | -54.198% |
| CytoDyn Inc. | 127.89 Million USD | 98.416% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -4745.539% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -29.304% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 81.663% |
| SYBLEU INC | 681.41 Thousand USD | -197.233% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 66.807% |
| International Stem Cell Corporation | 5.27 Million USD | 61.619% |
| Bioxytran, Inc. | 3.24 Million USD | 37.671% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -223.643% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 56.133% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 95.06% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 90.903% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 63.027% |
| Neutra Corp. | 973.52 Thousand USD | -108.046% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 93.02% |
| PureTech Health plc | 125.58 Million USD | 98.387% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 46.092% |
| IXICO plc | 1.9 Million USD | -6.583% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 90.134% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 98.04% |
| CSL Limited | 18.62 Billion USD | 99.989% |
| Cellectis S.A. | 249.36 Million USD | 99.188% |